The Pharmacogenomics in Childhood Asthma (PiCA) consortium is a research consortium that has been established in December 2013 by prof. dr. Anke-Hilse Maitland van der Zee and dr. Susanne Vijverberg to bring together asthma studies that have genetic data and treatment outcome measures. Asthma is the most common chronic disease in childhood. Although it cannot be cured, effective treatments are available. However, there is a large variability in treatment response which is partly due to genetic variances.
Studies are eligible to participate in the PiCA consortium if:
PiCA is a growing consortium. Currently, over 20 studies participate in the PiCA consortium.
For more information on the rationale and design of the consortium see: